Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

SEATTLE, December 26, 2025--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

Organisms sense and respond to changes in the environment through signal transduction pathways. Pathways like highly conserved Mitogen-Activated Protein Kinase (MAPK) pathways are composed of sensor ...

Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2. The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) ...

A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...

LONDON & NEW YORK, January 06, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today ...

Cancer immunity and immunotherapy research increasingly recognizes that chronic inflammation is a major driver of tumorigenesis, yet the complex and dynamic ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...